vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.1× ALNYLAM PHARMACEUTICALS, INC.). ALNYLAM PHARMACEUTICALS, INC. runs the higher net margin — 17.0% vs 17.0%, a 0.0% gap on every dollar of revenue. On growth, ALNYLAM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (84.9% vs 10.1%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $140.3M). Over the past eight quarters, ALNYLAM PHARMACEUTICALS, INC.'s revenue compounded faster (49.0% CAGR vs 15.2%).
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ALNY vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.2B |
| Net Profit | $186.4M | $203.5M |
| Gross Margin | 75.6% | — |
| Operating Margin | 12.0% | 21.2% |
| Net Margin | 17.0% | 17.0% |
| Revenue YoY | 84.9% | 10.1% |
| Net Profit YoY | 322.6% | 6.5% |
| EPS (diluted) | $1.44 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $773.7M | $1.0B | ||
| Q1 25 | $594.2M | $897.8M | ||
| Q4 24 | $593.2M | $1.1B | ||
| Q3 24 | $500.9M | $1.1B | ||
| Q2 24 | $659.8M | $1.0B | ||
| Q1 24 | $494.3M | $902.0M |
| Q4 25 | $186.4M | $203.5M | ||
| Q3 25 | $251.1M | $251.4M | ||
| Q2 25 | $-66.3M | $-718.5M | ||
| Q1 25 | $-57.5M | $-92.5M | ||
| Q4 24 | $-83.8M | $191.1M | ||
| Q3 24 | $-111.6M | $215.1M | ||
| Q2 24 | $-16.9M | $168.6M | ||
| Q1 24 | $-65.9M | $-14.6M |
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — | ||
| Q1 24 | 89.0% | — |
| Q4 25 | 12.0% | 21.2% | ||
| Q3 25 | 29.5% | 5.1% | ||
| Q2 25 | -2.1% | -65.6% | ||
| Q1 25 | 3.0% | -6.2% | ||
| Q4 24 | -17.7% | 17.5% | ||
| Q3 24 | -15.4% | 24.7% | ||
| Q2 24 | 7.4% | 19.5% | ||
| Q1 24 | -8.8% | 7.3% |
| Q4 25 | 17.0% | 17.0% | ||
| Q3 25 | 20.1% | 22.3% | ||
| Q2 25 | -8.6% | -68.7% | ||
| Q1 25 | -9.7% | -10.3% | ||
| Q4 24 | -14.1% | 17.6% | ||
| Q3 24 | -22.3% | 20.4% | ||
| Q2 24 | -2.6% | 16.5% | ||
| Q1 24 | -13.3% | -1.6% |
| Q4 25 | $1.44 | $3.34 | ||
| Q3 25 | $1.84 | $4.08 | ||
| Q2 25 | $-0.51 | $-11.74 | ||
| Q1 25 | $-0.44 | $-1.52 | ||
| Q4 24 | $-0.66 | $2.97 | ||
| Q3 24 | $-0.87 | $3.42 | ||
| Q2 24 | $-0.13 | $2.49 | ||
| Q1 24 | $-0.52 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $1.4B |
| Total DebtLower is stronger | — | $5.4B |
| Stockholders' EquityBook value | $789.2M | $4.3B |
| Total Assets | $5.0B | $11.7B |
| Debt / EquityLower = less leverage | — | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $966.4M | $2.4B | ||
| Q3 24 | $1.1B | $2.2B | ||
| Q2 24 | $968.5M | $1.4B | ||
| Q1 24 | $681.9M | $1.4B |
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | $789.2M | $4.3B | ||
| Q3 25 | $233.9M | $4.0B | ||
| Q2 25 | $250.6M | $3.7B | ||
| Q1 25 | $115.4M | $4.2B | ||
| Q4 24 | $67.1M | $4.1B | ||
| Q3 24 | $32.4M | $4.2B | ||
| Q2 24 | $-3.1M | $3.8B | ||
| Q1 24 | $-219.3M | $3.7B |
| Q4 25 | $5.0B | $11.7B | ||
| Q3 25 | $4.9B | $11.4B | ||
| Q2 25 | $4.6B | $10.9B | ||
| Q1 25 | $4.2B | $11.5B | ||
| Q4 24 | $4.2B | $12.0B | ||
| Q3 24 | $4.2B | $12.3B | ||
| Q2 24 | $4.0B | $11.4B | ||
| Q1 24 | $3.8B | $11.3B |
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $163.6M | $362.5M |
| Free Cash FlowOCF − Capex | $140.3M | $345.8M |
| FCF MarginFCF / Revenue | 12.8% | 28.9% |
| Capex IntensityCapex / Revenue | 2.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.88× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $465.4M | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $163.6M | $362.5M | ||
| Q3 25 | $325.1M | $474.6M | ||
| Q2 25 | $153.7M | $88.9M | ||
| Q1 25 | $-118.3M | $429.8M | ||
| Q4 24 | $-94.7M | $398.6M | ||
| Q3 24 | $43.7M | $398.7M | ||
| Q2 24 | $124.2M | $331.4M | ||
| Q1 24 | $-81.5M | $267.2M |
| Q4 25 | $140.3M | $345.8M | ||
| Q3 25 | $313.0M | $459.4M | ||
| Q2 25 | $139.4M | $75.9M | ||
| Q1 25 | $-127.3M | $415.9M | ||
| Q4 24 | $-103.8M | $385.3M | ||
| Q3 24 | $39.5M | $388.0M | ||
| Q2 24 | $116.1M | $324.3M | ||
| Q1 24 | $-94.5M | $260.3M |
| Q4 25 | 12.8% | 28.9% | ||
| Q3 25 | 25.1% | 40.8% | ||
| Q2 25 | 18.0% | 7.3% | ||
| Q1 25 | -21.4% | 46.3% | ||
| Q4 24 | -17.5% | 35.4% | ||
| Q3 24 | 7.9% | 36.8% | ||
| Q2 24 | 17.6% | 31.7% | ||
| Q1 24 | -19.1% | 28.9% |
| Q4 25 | 2.1% | 1.4% | ||
| Q3 25 | 1.0% | 1.3% | ||
| Q2 25 | 1.8% | 1.2% | ||
| Q1 25 | 1.5% | 1.5% | ||
| Q4 24 | 1.5% | 1.2% | ||
| Q3 24 | 0.8% | 1.0% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 2.6% | 0.8% |
| Q4 25 | 0.88× | 1.78× | ||
| Q3 25 | 1.29× | 1.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | — | 1.97× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALNY
| TTR | $858.3M | 78% |
| Rare | $136.4M | 12% |
| GIVLAARI | $56.3M | 5% |
| Collaborative Arrangement | $40.9M | 4% |
| ONPATTRO | $12.0M | 1% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
